Hostname: page-component-586b7cd67f-g8jcs Total loading time: 0 Render date: 2024-11-25T06:57:21.312Z Has data issue: false hasContentIssue false
  • English
  • Français

Proteasome Inhibitor Lactacystin Induces Cholinergic Degeneration

Published online by Cambridge University Press:  02 December 2014

Hai-Yan Zhou ,
Yu-Yan Tan ,
Zhi-Quan Wang ,
Gang Wang ,
Guo-Qiang Lu  and
Sheng-Di Chen
Hai-Yan Zhou
Affiliation:
Department of Neurology & Institute of Neurology, Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine
Yu-Yan Tan
Affiliation:
Department of Neurology & Institute of Neurology, Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine
Zhi-Quan Wang
Affiliation:
Institute of Health Science, Shanghai Institutes of Biological Sciences, Chinese Academy of Science & Shanghai Jiaotong University School of Medicine, Shanghai, China
Gang Wang
Affiliation:
Department of Neurology & Institute of Neurology, Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine
Guo-Qiang Lu
Affiliation:
Department of Neurology & Institute of Neurology, Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine
Sheng-Di Chen*
Affiliation:
Department of Neurology & Institute of Neurology, Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine Institute of Health Science, Shanghai Institutes of Biological Sciences, Chinese Academy of Science & Shanghai Jiaotong University School of Medicine, Shanghai, China
*
Department of Neurology & Institute of Neurology, Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 20025, China.
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Objective:

Ubiquitin proteasome system dysfunction is believed to play an important role in the development of Parkinson's disease (PD), and almost all studies till now have mainly focused on the susceptibility of dopaminergic neurons to proteasome inhibition. However, in fact, there are many other types of neurons such as cholinergic ones involved in PD. In our present study, we attempt to figure out what effect the failure of ubiquitin proteasome function would execute on cholinergic cells in culture.

Methods:

We treated cholinergic cells in culture with various doses of lactacystin. Then MTT assay was used to evaluate the cellular viability and the Annexin V-PI method was used to detect apoptosis. Both cellular soluble and insoluble polyubiquitinated proteins were detected by western blot. Furthermore, the mitochondrial membrane potential was analyzed using JC-1 and the intracellular production of reactive oxygen species (ROS) was determined using the fluorescent probe CM-H2DCFDA.

Results:

We found that low doses of lactacystin were enough to induce significant apoptotic cell death, disturb the mitochondrial membrane potential, and cause oxidative stress. We also found that the amounts of polyubiquitinated proteins dramatically increased with high doses, although the loss of cells did not increase accordingly.

Conclusions:

Our results suggest that cholinergic cells are sensitive to ubiquitin proteasome system dysfunction, which exerts its toxic effect by causing mitochondrial dysfunction and subsequent oxidative stress, not through polyubiquitinated proteins accumulation.

Type
Research Article
Information
Canadian Journal of Neurological Sciences , Volume 37 , Issue 2 , March 2010 , pp. 229 - 234
Copyright
Copyright © The Canadian Journal of Neurological 2010

References

1. Dawson, TM, Dawson, VL. Molecular pathways of neurodegeneration in Parkinson’s disease. Science. 2003;302(5646):819–22.Google Scholar
2. McNaught, KS, Olanow, CW. Proteolytic stress: a unifying concept for the etiopathogenesis of Parkinson’s disease. Ann Neurol. 2003;53 Suppl 3:S73–84.Google Scholar
3. Moore, DJ, West, AB, Dawson, VL, Dawson, TM. Molecular pathophysiology of Parkinson’s disease. Annu Rev Neurosci. 2005;28:57–87.CrossRefGoogle ScholarPubMed
4. Polymeropoulos, MH, Lavedan, C, Leroy, E, Ide, SE, Dehejia, A, Dutra, A, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science. 1997;276(5321): 2045–7.Google Scholar
5. Kitada, T, Asakawa, S, Hattori, N, Matsumine, H, Yamamura, Y, Minoshima, S, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 1998;392(6676):605–8.CrossRefGoogle Scholar
6. Leroy, E, Boyer, R, Auburger, G, Leube, B, Ulm, G, Mezey, E, et al. The ubiquitin pathway in Parkinson’s disease. Nature. 1998;395(6701):451–2.Google Scholar
7. Bonifati, V, Rizzu, P, van Baren, MJ, Schaap, O, Breedveld, GJ, Krieger, E, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science. 2003;299(5604):256–9.Google Scholar
8. McNaught, KS, Jenner, P. Proteasomal function is impaired in substantia nigra in Parkinson’s disease. Neurosci Lett. 2001;297(3):191–4.Google Scholar
9. McNaught, KS, Belizaire, R, Jenner, P, Olanow, CW, Isacson, O. Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson’s disease. Neurosci Lett. 2002;326(3):155–8.Google Scholar
10. McNaught, KS, Belizaire, R, Isacson, O, Jenner, P, Olanow, CW. Altered proteasomal function in sporadic Parkinson’s disease. Exp Neurol. 2003;179(1):38–46.Google Scholar
11. Fornai, F, Lenzi, P, Gesi, M, Ferrucci, M, Lazzeri, G, Busceti, CL, et al. Fine structure and biochemical mechanisms underlying nigrostriatal inclusions and cell death after proteasome inhibition. J Neurosci. 2003;23(26):8955–66.Google Scholar
12. McNaught, KS, Perl, DP, Brownell, AL, Olanow, CW. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson’s disease. Ann Neurol. 2004;56(1):149–62.CrossRefGoogle ScholarPubMed
13. Schapira, AH, Cleeter, MW, Muddle, JR, Workman, JM, Cooper, JM, King, RH. Proteasomal inhibition causes loss of nigral tyrosine hydroxylase neurons. Ann Neurol. 2006;60(2):253–5.Google Scholar
14. Mathur, BN, Neely, MD, Dyllick-Brenzinger, M, Tandon, A, Deutch, AY. Systemic administration of a proteasome inhibitor does not cause nigrostriatal dopamine degeneration. Brain Res. 2007;1168:83–9.Google Scholar
15. Landau, AM, Kouassi, E, Siegrist-Johnstone, R, Desbarats, J. Proteasome inhibitor model of Parkinson’s disease in mice is confounded by neurotoxicity of the ethanol vehicle. Mov Disord. 2007;22(3):403–7.Google Scholar
16. Kordower, JH, Kanaan, NM, Chu, Y, Suresh Babu, R, Stansell, J 3rd, Terpstra, BT, et al. Failure of proteasome inhibitor administration to provide a model of Parkinson’s disease in rats and monkeys. Ann Neurol. 2006;60(2):264–8.Google Scholar
17. Manning-Boğ, AB, Reaney, SH, Chou, VP, Johnston, LC, McCormack, AL, Johnston, J, et al. Lack of nigrostriatal pathology in a rat model of proteasome inhibition. Ann Neurol. 2006;(2):256–60.Google Scholar
18. Hawlitschka, A, Haas, SJ, Schmitt, O, Weiss, DG, Wree, A. Effects of systemic PSI administration on catecholaminergic cells in the brain, adrenal medulla and carotid body in Wistar rats. Brain Res. 2007;1173:137–44.Google Scholar
19. Braak, H, Del Tredici, K, Rub, U, de Vos, RA, Jansen Steur, EN, Braak, E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003;24(2):197–211.Google Scholar
20. Ahlskog, JE. Challenging conventional wisdom: the etiologic role of dopamine oxidative stress in Parkinson’s disease. Mov Disord. 2005;20(3):271–82.CrossRefGoogle ScholarPubMed
21. Zarow, C, Lyness, SA, Mortimer, JA, Chui, HC. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol. 2003;60(3):337–41.Google Scholar
22. Rideout, HJ, Lang-Rollin, IC, Savalle, M, Stefanis, L. Dopaminergic neurons in rat ventral midbrain cultures undergo selective apoptosis and form inclusions, but do not up-regulate iHSP70, following proteasomal inhibition. J Neurochem. 2005;93(5): 1304–13.Google Scholar
23. Suh, J, Lee, YA, Gwag, BJ. Induction and attenuation of neuronal apoptosis by proteasome inhibitors in murine cortical cell cultures. J Neurochem. 2005;95(3):684–94.Google Scholar
24. Lang-Rollin, I, Vekrellis, K, Wang, Q, Rideout, HJ, Stefanis, L. Application of proteasomal inhibitors to mouse sympathetic neurons activates the intrinsic apoptotic pathway. J Neurochem. 2004;90(6):1511–20.Google Scholar
25. Qiu, JH, Asai, A, Chi, S, Saito, N, Hamada, H, Kirino, T. Proteasome inhibitors induce cytochrome c-caspase-3-like proteasemediated apoptosis in cultured cortical neurons. J Neurosci. 2000;20(1):259–65.Google Scholar
26. Sullivan, PG, Dragicevic, NB, Deng, JH, Bai, Y, Dimayuga, E, Ding, Q, et al. Proteasome inhibition alters neural mitochondrial homeostasis and mitochondria turnover. J Biol Chem. 2004;279(20):20699–707.Google Scholar
27. Wagenknecht, B, Hermisson, M, Groskurth, P, Liston, P, Krammer, PH, Weller, M. Proteasome inhibitor-induced apoptosis of glioma cells involves the processing of multiple caspases and cytochrome c release. J Neurochem. 2000;75(6):2288–97.Google Scholar
28. Goldbaum, O, Vollmer, G, Richter-Landsberg, C. Proteasome inhibition by MG-132 induces apoptotic cell death and mitochondrial dysfunction in cultured rat brain oligodendrocytes but not in astrocytes. Glia. 2006;53(8):891–901.Google Scholar
29. Halliwell, B. Hypothesis: proteasomal dysfunction: a primary event in neurodegeneration that leads to nitrative and oxidative stress and subsequent cell death. Ann N Y Acad Sci. 2002;962:182–94.Google Scholar
30. Kikuchi, S, Shinpo, K, Tsuji, S, Takeuchi, M, Yamagishi, S, Makita, Z, et al. Effect of proteasome inhibitor on cultured mesencephalic dopaminergic neurons. Brain Res. 2003;964(2):228–36.Google Scholar
31. Mytilineou, C, McNaught, KS, Shashidharan, P, Yabut, J, Baptiste, RJ, Parnandi, A, et al. Inhibition of proteasome activity sensitizes dopamine neurons to protein alterations and oxidative stress. J Neural Transm. 2004;111(10-11):1237–51.Google Scholar
32. Lev, N, Melamed, E, Offen, D. Proteasomal inhibition hypersensitizes differentiated neuroblastoma cells to oxidative damage. Neurosci Lett. 2006;399(1-2):27–32.Google Scholar
33. Yamamoto, N, Sawada, H, Izumi, Y, Kume, T, Katsuki, H, Shimohama, S, et al. Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease. J Biol Chem. 2007;282(7):4364–72.Google Scholar
34. Hung, CC, Davison, EJ, Robinson, PA, Ardley, HC. The aggravating role of the ubiquitin-proteasome system in neurodegenerative disease. Biochem Soc Trans. 2006;34(Pt 5):743–5.Google Scholar
35. Ardley, HC, Hung, CC, Robinson, PA. The aggravating role of the ubiquitin-proteasome system in neurodegeneration. FEBS Lett. 2005;579(3):571–6.Google Scholar
36. Shimura, H, Hattori, N, Kubo, S, Yoshikawa, M, Kitada, T, Matsumine, H, et al. Immumohistochemical and subcellular localization of parkin protein: absence of protein in autosomal recessive juvenile parkinsonism patients. Ann Neurol. 1999;45(5):668–72.Google Scholar
37. Schlossmacher, MG, Frosch, MP, Gai, WP, Medina, M, Sharma, N, Forno, L, et al. Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. Am J Pathol. 2002;160(5):1655–67.Google Scholar
38. Rideout, HJ, Wang, Q, Park, DS, Stefanis, L. Cyclin-dependent kinase activity is required for apoptotic death but not inclusion formation in cortical neurons after proteasomal inhibition. J Neurosci. 2003;23(4):1237–45.Google Scholar
39. Dietrich, P, Rideout, HJ, Wang, Q, Stefanis, L. Lack of p53 delays apoptosis, but increases ubiquitinated inclusions, in proteasomal inhibitor-treated cultured cortical neurons. Mol Cell Neurosci. 2003;24(2):430–41.Google Scholar